Cargando…

POLE exonuclease domain mutations in endometrial carcinoma: a case report

Endometrial carcinoma (EC) harboring POLE exonuclease domain mutations occurs in 5-15% of ECs and frequently affects young women with low body mass index (BMI). It presents at early stage as high grade endometrioid histotype with intense tumor infiltrating lymphocytes and has good clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pasciuto, Maria Paola, Felicioni, Lara, Zampacorta, Claudia, Ferro, Benedetta, Di Marino, Pietro, Primavera, Francesca Chiara, Lucidi, Alessandro, Rossetti, Rebecca, Barbareschi, Mattia, Marchetti, Antonio, Buttitta, Fiamma, D’Angelo, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pacini Editore srl 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462992/ https://www.ncbi.nlm.nih.gov/pubmed/37216304 http://dx.doi.org/10.32074/1591-951X-872

Ejemplares similares

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
por: Buttitta, Fiamma, et al.
Publicado: (2023)

NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies
por: Marchetti, Antonio, et al.
Publicado: (2022)

Placental site trophoblastic tumor (PSTT): a case report and review of the literature
por: Zampacorta, Claudia, et al.
Publicado: (2023)

An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments
por: Marchetti, Antonio, et al.
Publicado: (2019)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit
por: Dong, Sharlene, et al.
Publicado: (2022)

First description of ultramutated endometrial cancer caused by germline loss-of-function and somatic exonuclease domain mutations in POLE gene
por: Rosa, Reginaldo Cruz Alves, et al.
Publicado: (2020)

Mutational Profile of GNAQ (Q209) in Human Tumors
por: Lamba, Simona, et al.
Publicado: (2009)

Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1
por: Mur, Pilar, et al.
Publicado: (2023)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer()()
por: Gasparini, Giampietro, et al.
Publicado: (2014)

A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report
por: Cui, Jiantao, et al.
Publicado: (2023)

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment
por: Buttitta, Fiamma, et al.
Publicado: (2020)

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
por: Marchetti, Antonio, et al.
Publicado: (2012)

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
por: Marchetti, Antonio, et al.
Publicado: (2014)

Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps
por: Elsayed, Fadwa A., et al.
Publicado: (2019)

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response
por: Temko, Daniel, et al.
Publicado: (2018)

DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer
por: Church, David N., et al.
Publicado: (2013)

Phenotype of POLE-mutated endometrial cancer
por: Imboden, Sara, et al.
Publicado: (2019)

Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer
por: Mo, Shaobo, et al.
Publicado: (2020)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Chen, Yan‐Xing, et al.
Publicado: (2021)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Interpretation of somatic POLE mutations in endometrial carcinoma
por: León‐Castillo, Alicia, et al.
Publicado: (2020)

Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network
por: Marchetti, Antonio, et al.
Publicado: (2021)

Characterization of hotspot exonuclease domain mutations in the DNA polymerase ϵ gene in endometrial cancer
por: Tian, Wenjuan, et al.
Publicado: (2022)

Gastric (gastrointestinal)-type endometrial adenocarcinoma presenting as a solitary endometrial polyp: a case report and literature review on a novel and potentially aggressive endometrial cancer histotype
por: Bragantini, Emma, et al.
Publicado: (2023)

POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East
por: Siraj, Abdul K., et al.
Publicado: (2020)

Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer
por: Fang, Hu, et al.
Publicado: (2020)

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
por: Wen, Lei, et al.
Publicado: (2022)

Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
por: Church, David N., et al.
Publicado: (2014)

POLE proofreading mutation, immune response and prognosis in endometrial cancer
por: van Gool, Inge C., et al.
Publicado: (2015)

POLE Mutation Characteristics in a Chinese Cohort with Endometrial Carcinoma
por: Li, Yiran, et al.
Publicado: (2020)

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain
por: Huang, Fangjin, et al.
Publicado: (2020)

Clinicopathologic and protein markers distinguishing the “polymerase epsilon exonuclease” from the “copy number low” subtype of endometrial cancer
por: Kim, Kidong, et al.
Publicado: (2022)

Mechanistic decoupling of exonuclease III multifunctionality into AP endonuclease and exonuclease activities at the single-residue level
por: Lee, Donghun, et al.
Publicado: (2022)

The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity
por: Labrousse, Guillaume, et al.
Publicado: (2023)

Pole to Pole Surgery in Ocular Trauma: Standardizing Surgical Steps
por: Frisina, Rino, et al.
Publicado: (2022)

Exonuclease containment by SUMO plus ubiquitin
por: Naegeli, Hanspeter
Publicado: (2015)

Inhibition of Arenaviridae nucleoprotein exonuclease by bisphosphonate
por: Nguyen, Thi Hong Van, et al.
Publicado: (2022)

Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units
por: Lazzaro, Carlo, et al.
Publicado: (2023)

Architecture of the Pol III–clamp–exonuclease complex reveals key roles of the exonuclease subunit in processive DNA synthesis and repair
por: Toste Rêgo, Ana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0vbjlukum61h232vu846s4msb9